IGC Pharma的股东们批准了关键提案,包括新的董事和股票计划,因为它推进了AI驱动的阿尔茨海默氏病和代谢药物试验。 IGC Pharma’s shareholders approved key proposals, including new directors and a stock plan, as it advances AI-driven Alzheimer’s and metabolic drug trials.

2025年10月10日,IGC Pharma宣布,股东在其年度会议上批准了所有提案,包括选举两名新董事、批准其审计员、批准500万股股股奖励计划,以及将核准的共同股份从1.5亿增加到6亿。 IGC Pharma announced on October 10, 2025, that shareholders approved all proposals at its annual meeting, including the election of two new directors, ratification of its auditor, approval of a 5 million-share stock incentive plan, and a move to increase authorized common shares from 150 million to 600 million. 该公司开发AI驱动的阿尔茨海默氏病和新陈代谢紊乱疗法,继续其第二阶段对IGC-AD1进行测试,以刺激阿尔茨海默氏痴呆症,并增加了针对氨基甲状腺质和蛋白质的方案。 The company, developing AI-driven therapies for Alzheimer’s and metabolic disorders, continues its Phase 2 trial of IGC-AD1 for agitation in Alzheimer’s dementia, with additional programs targeting amyloid plaques and tau proteins. 它持有30多份专利申请和12份专利。 It holds over 30 patent applications and 12 patents. 前瞻性声明指出了各种风险,包括监管延误、商业化挑战和AI性能不确定性。 Forward-looking statements note risks including regulatory delays, commercialization challenges, and AI performance uncertainties.